Incidence of precancerous cervical lesions decreasing among young women
the ONA take:
According to a new study published in the journal Cancer, researchers have found that the incidence of high-grade cervical lesions in young women has significantly decreased, but the declines were likely due to reduced screening.
Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN2+) lesions can be monitored as early indicators of the effect of human papillomavirus (HPV) vaccines.
For the study, researchers identified over 9,000 cases of CIN2+ among patients aged 18 to 39 years in California, Connecticut, New York, and Oregon.
Researchers found that from 2008 to 2012, the rates of CIN2+ significantly decreased among women aged 18 to 20 years in all four states and among 21- to 29-year-old women in Connecticut and New York.
Researchers found that screening rates also declined during that time period, suggesting that the decline in these cervical lesions is most likely due to fewer screenings, but could potentially be an effect of vaccination as well.
Incidence of high-grade cervical lesions in young women has significantly decreased, but the declines were likely due to reduced screening.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|